Tyra Biosciences Inc (TYRA) is trading up at $20.87 (+1.31%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Operating income | −$9.30M | −$26.3M | −$58.9M | −$79.9M | −$104.2M | −$132.8M |
| Net income | −$9.34M | −$26.3M | −$55.3M | −$69.1M | −$86.5M | −$119.9M |
| EPS (diluted) | −$6.05 | −$1.91 | −$1.32 | −$1.62 | −$1.51 | −$2.01 |
| Balance sheet | ||||||
| Cash and equivalents | $15.2M | $302.2M | $251.2M | $58.0M | $92.0M | $77.4M |
| Total assets | $16.0M | $306.7M | $266.2M | $225.9M | $363.6M | $282.6M |
| Total liabilities | $2.00M | $4.96M | $8.35M | $21.6M | $20.4M | $23.4M |
| Shareholders' equity | −$13.6M | $301.7M | $257.8M | $204.3M | $343.2M | $259.2M |
| Cash flow | ||||||
| Operating cash flow | −$7.76M | −$23.7M | −$50.3M | −$50.1M | −$69.8M | −$95.1M |
| Capital expenditure | $312.0K | $661.0K | $559.0K | $770.0K | $664.0K | $141.0K |
| Free cash flow | −$8.07M | −$24.4M | −$50.8M | −$50.9M | −$70.4M | −$95.3M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$28.6M | −$29.7M | −$31.9M | −$31.5M | −$32.9M | −$36.5M | −$42.0M | −$49.0M |
| Net income | −$24.0M | −$25.6M | −$28.1M | −$28.1M | −$29.9M | −$33.8M | −$39.3M | −$45.6M |
| EPS (diluted) | −$0.41 | −$0.43 | −$0.47 | −$0.47 | −$0.50 | −$0.57 | −$0.64 | −$0.69 |
| Balance sheet | ||||||||
| Cash and equivalents | $103.9M | $92.0M | $100.7M | $98.5M | $62.0M | $77.4M | $85.0M | $73.8M |
| Total assets | $380.6M | $363.6M | $343.5M | $321.5M | $301.9M | $282.6M | $412.0M | $383.4M |
| Total liabilities | $18.3M | $20.4M | $19.9M | $19.4M | $21.3M | $23.4M | $24.5M | $29.7M |
| Shareholders' equity | $362.3M | $343.2M | $323.5M | $302.1M | $280.5M | $259.2M | $387.6M | $353.7M |
| Cash flow | ||||||||
| Operating cash flow | −$17.9M | −$19.6M | −$25.5M | −$23.7M | −$22.4M | −$23.6M | −$32.6M | −$31.1M |
| Capital expenditure | $52.0K | $6.00K | $14.0K | $31.0K | $39.0K | $57.0K | $88.0K | $66.0K |
| Free cash flow | −$17.9M | −$19.6M | −$25.5M | −$23.7M | −$22.4M | −$23.7M | −$32.7M | −$31.1M |
From Tyra Biosciences Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Tyra Biosciences Inc in our feed yet.